# Eytan M. Stein

Source: https://onco.cc/people/eytan-stein/  
OnCo record `eytan-stein` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Led the enasidenib and revumenib trials that brought IDH2 and menin inhibitors to acute leukaemia.

## Summary

Eytan Stein led the first-in-human trial of the IDH2 inhibitor enasidenib, which won approval for relapsed IDH2-mutant AML, and was a lead investigator of AUGMENT-101, the trial establishing the menin inhibitor revumenib for KMT2A-rearranged and NPM1-mutant acute leukaemia. He heads the leukaemia service at MSKCC and directs early-phase leukaemia drug development.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: aml; menin; idh; early-phase
- Role: Chief, Leukemia Service, Memorial Sloan Kettering Cancer Center
- Specialisms: Acute myeloid leukaemia; IDH inhibitors; Menin inhibitors; Early drug development

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Stein%20EM%5BAuthor%5D%20enasidenib%20OR%20revumenib

## Connected records

- cancers: [Acute lymphoblastic leukaemia](https://onco.cc/cancers/all-leukemia/), [Acute myeloid leukaemia](https://onco.cc/cancers/aml/)
- targets: [IDH1 / IDH2](https://onco.cc/targets/idh/), [Menin](https://onco.cc/targets/menin/)
- drugs: [Revumenib](https://onco.cc/drugs/revumenib/)
- institutions: [Memorial Sloan Kettering Cancer Center](https://onco.cc/institutions/mskcc/)
- trials: [AUGMENT-101](https://onco.cc/trials/augment-101/)
- key papers: [AUGMENT-101: revumenib, the first menin inhibitor, in relapsed leukaemias driven by KMT2A rearrangement or NPM1 mutation](https://onco.cc/key-papers/paper-augment-101-revumenib-menin-nature-2023/)
- journals: [Blood](https://onco.cc/journals/blood/)
- roadmaps: [Epigenetic therapy roadmap: loosening silenced genes → mutation-specific enzymes → editing the epigenome](https://onco.cc/roadmaps/epigenetics-roadmap/)

---
JSON: https://onco.cc/api/v1/entities/eytan-stein.json